Chemistry:Forvisirvat
From HandWiki
Forvisirvat (INN, USAN; developmental code name SP-624) is a sirtuin-6 (SIRT6) activator which is under development for the treatment of major depressive disorder and schizophrenia.[1][2][3][4][5] It is taken by mouth.[1] As of January 2025, forvisirvat is in phase 2/3 clinical trials for major depressive disorder and is in phase 1/2 clinical trials for schizophrenia.[1][2][4] It is under development by Sirtsei Pharmaceuticals and Arrivo BioVentures.[1][2][5]
See also
References
- ↑ 1.0 1.1 1.2 1.3 "SP 624". 29 August 2024. https://adisinsight.springer.com/drugs/800059680.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on SP-624 with Synapse". 21 September 2024. https://synapse.patsnap.com/drug/5e9cf60c85324e4a8747e839e82af610.
- ↑ "Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults". Clinical Pharmacology in Drug Development 14 (1): 18–25. 2025. doi:10.1002/cpdd.1488. ISSN 2160-763X. PMID 39587867.
- ↑ 4.0 4.1 "Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead". Acta Pharmaceutica Sinica. B 14 (3): 1009–1029. March 2024. doi:10.1016/j.apsb.2023.10.023. PMID 38486982.
- ↑ 5.0 5.1 "Depression treatment shows 'robust efficacy' in women in phase 2 trial". 19 October 2022. https://www.healio.com/news/psychiatry/20221019/depression-treatment-shows-robust-efficacy-in-women-in-phase-2-trial.
 |  |
